SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Skye Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.53−0.02 (-1.29%)
Close on Oct 19, 2026
- Market cap
- $60.73M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 167.0% | -1313.7% | -126.8% | |
| Return on assets | -165.8% | -281.1% | -110.7% | |
| Current ratio | 0.42 | 3.38 | 3.30 | |
| Interest coverage | – | -8.9× | – | |
| Diluted shares | 0M | 1M | 40M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Skye Bioscience generated $101.47M from operations and spent $1.74M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$101.47M
Used
$1.74M
Capital expenditure$1.74M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$55.92M
- Cash generatingOperating cash flow above zero-$43.06M
- Return on assets improvedROA up on the prior year-222.5% → -76.9%
- Earnings backed by cashOperating cash flow above net income-$43.06M vs -$55.92M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose16.32 → 3.30
- No dilutionShare count did not rise36M → 40M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –